ANI Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, ANI Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $108.38. The average 1-year stock price forecast is 48.81% higher than the current stock price, while the lowest is $90 (+23.58%) and the highest is $121 (+66.14%).

Price Target: $108.38 (+48.81%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$90	$108.38	$109.5	$121
Change	+23.58%	+48.81%	+50.35%	+66.14%

Analyst Ratings

The average analyst rating for ANI Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Mar '26	Apr '26	May '26	Jun '26	Jul '26	Aug '26
Strong Buy	4	4	4	4	4	4
Buy	3	3	3	3	3	3
Hold	1	1	1	0	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	8	8	7	8	8

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Glen Santangelo Barclays	Barclays	Buy Maintains $100	Buy	Maintains	$100	+37.31%	Aug 26, 2026
Brandon Folkes H.C. Wainwright	H.C. Wainwright	Buy Reiterates $121	Buy	Reiterates	$121	+66.14%	Aug 11, 2026
Unknown Analyst Jefferies No rating	Jefferies	Buy Reiterates $120	Buy	Reiterates	$120	+64.77%	Aug 10, 2026
Ekaterina Knyazkova J.P. Morgan	J.P. Morgan	Buy Reiterates $115	Buy	Reiterates	$115	+57.90%	Aug 10, 2026
Gary Nachman Canaccord Genuity	Canaccord Genuity	Hold Maintains $91 → $90	Hold	Maintains	$91 → $90	+23.58%	Aug 10, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

1.10B

from 883.37M

24.85%

from 883.37M

Revenue Next Year

1.23B

from 1.10B

11.50%

from 1.10B

EPS This Year

9.28

from 7.89

17.67%

from 7.89

EPS Next Year

10.44

from 9.28

12.47%

from 9.28

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	216.14M	316.39M	486.82M	614.38M	883.37M	1.10B
Revenue Growth	3.68%	46.38%	53.87%	26.20%	43.78%	24.85%
Gross Profit	115.53M	177.60M	305.30M	377.77M	542.06M	670.29M
Gross Margin	53.45%	56.13%	62.71%	61.49%	61.36%	60.78%
Operating Income	-28.17M	-25.73M	49.53M	33.92M	83.33M	261.04M
Net Income	-42.60M	-47.90M	18.78M	-18.52M	78.34M	113.15M
EPS	-	-	-	-	7.89	9.28
EPS Growth	-	-	-	-	51.73%	17.67%
Forward PE	12.86	14.79	14.04	10.72	10.03	7.84
Free Cash Flow	-28.62M	-38.70M	114.36M	42.67M	119.42M	136.05M
No. Analysts	-	-	-	-	-	7

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	1.1B
Avg	1.1B
Low	1.1B

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	26.1%
Avg	24.9%
Low	23.7%

EPS Forecast

Chart

EPS	2026	2027	2028
High	9.37
Avg	9.28
Low	9.20

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	18.8%
Avg	17.7%
Low	16.6%